Sangamo BioSciences | SGMO - Loan Capital


Sangamo BioSciences reported $0 in Loan Capital for its fiscal quarter ending in June of 2022.





Loan Capital Change Date
Alaunos Therapeutics USD 4.47M 5.85M Jun/2022
Alnylam Pharmaceuticals USD 2.47B 6.56M Jun/2026
Alterity Therapeutics Limited AUD 43.68K 59.53K Dec/2025
Amgen USD 51.86B 27M Jun/2026
Bayer EUR 31.16B 480M Jun/2026
BioCryst Pharmaceuticals USD 395.4M 203K Jun/2026
Biogen USD 7.29B 1B Jun/2026
BioMarin Pharmaceutical USD 3.53B 2.1B Jun/2026
Cipla INR 3.82B 840.2M Mar/2026
Clal Biotechnology ILS 25.96M 18.48M Dec/2023
Compugen USD 0 0 Dec/2024
CSL USD 10.42B 273M Dec/2025
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 13.95B 65M Jun/2026
Grifols EUR 9.95B 722.93M Dec/2025
Ionis Pharmaceuticals USD 1.91B 6.62M Jun/2026
J&J USD 37.34B 183M Jun/2026
Karyopharm Therapeutics USD 264.49M 13.73M Mar/2026
Merck USD 51.08B 4.41B Jun/2026
Novartis USD 37.49B 42M Jun/2026
Omeros USD 403.72M 27.2M Jun/2024
Pfizer USD 60.5B 70M Jun/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 14.65B 806M Jun/2026
Sarepta Therapeutics USD 847.62M 9.46M Jun/2026
Tectonic Therapeutic USD 17K 26K Mar/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025